NCT06174753

Dapagliflozin in STEMI

The University of Ottawa Dapagliflozin in STEMI Randomized Clinical Trial

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 256 (estimated)
• Sponsor: Ottawa Heart Institute Research Corporation · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to assess the safety and efficacy of SGLT2i in limiting infarct size in patients with STEMI referred for PPCI. Eligible STEMI patients enrolled into the trial will be randomized to a SGLT2i or placebo. Cardiovascular Magnetic Resonance (CMR) imaging will be used to determine the infarct size.

Detailed description

DAPA STEMI is a single center, randomized, double-blind, parallel group study in which eligible participants with a STEMI and undergoing PPCI will be recruited and randomly assigned to dapagliflozin or placebo to take for 7 days. Participants will be prescribed study treatment i.e. dapagliflozin (10 mg) or placebo daily for 7 days. A CMR will be obtained at day 3-5 to assess for infarct size. Participants will have follow-up visits at 30, 90, and 180 days to assess for cardiovascular events.

Conditions

• ST Elevation Myocardial Infarction
• Myocardial Infarction

Interventions

Type	Name	Description
DRUG	Dapagliflozin 10mg Tab	Dapagliflozin 10 mg daily X 7 days
DIAGNOSTIC_TEST	CMR	CMR 3-5 days post randomization

Timeline

• Start date: 2025-01-20
• Primary completion: 2027-06-01
• Completion: 2027-12-01
• First posted: 2023-12-18
• Last updated: 2026-02-20

Locations

1 site across 1 country: Canada